Literature DB >> 34327701

Routine histopathology of septal myectomy for hypertrophic obstructive cardiomyopathy in a greek cohort.

Nikolaos S Ioakeimidis1, Antonios Pitsis2, Dimitrios Ntelios3, Thomas Zegkos3, Timotheos Kelpis2, Theodora Papamitsou4, Despoina Parcharidou3, Georgios Efthimiadis3, Soultana Meditskou4.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a diverse inherited disease affecting 1 in 500 individuals irrespective of gender and ethnicity. A fraction of HCM patients will eventually develop drug refractory dynamic obstruction of the left ventricular outflow tract. For such patients, septal myectomy is the procedure of choice to alleviate their symptoms and improve their quality of life. The current histopathological study, the first from the Greek region, aims to examine the hallmark histopathological characteristics of Hypertrophic Obstructive Cardiomyopathy in a population of patients undergoing septal myectomy at a single center over a ten year period. Medical records and histopathology specimens of thirty nine (n=39) patients were evaluated. The sample comprised 22 males (56.4%) and 17 females (43.6%). Mean patient age at myectomy was 53.9±16.7 years, ranging from 12 to 79 years. Maximal IVS thickness on echocardiography was available for 35 patients with a median value of 2.08cm. Peak resting LVOT Pressure Gradient was available for 33 patients with a mean value of 104.88±44.20 mmHg. Central tendency of each histopathological attribute expressed as the median value was: moderate for myocyte hypertrophy, mild for cytoplasmic vacuolization, moderate for subendocardial fibrosis, moderate for interstitial fibrosis, mild for replacement fibrosis, moderate for myofibrillar disarray and mild for capillary stenosis. Myocyte hypertrophy, present in all specimens, was positively correlated with maximal IVS thickness (tau-b=0.43, p=0.002). Replacement fibrosis was positively correlated with the grade of microvascular stenosis (tau-b=0.45, p=0.004). LVEF was negatively correlated with the grade of interstitial fibrosis (tau-b=-0.43, p=0.035) and with the extent of myocardial fiber disarray (tau-b=-0.42, p=0.034). Histopathological attributes were not correlated with patient gender or age thus proving that HCM has a histological phenotype unique to each patient, mainly depending on each specific sarcomeric mutation.

Entities:  

Mesh:

Year:  2021        PMID: 34327701     DOI: 10.14670/HH-18-369

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  24 in total

1.  Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience.

Authors:  Georgios K Efthimiadis; Antonis Pitsis; Efstathios D Pagourelias; Vasileios Kamperidis; Timotheos Kelpis; Soultana Meditskou; Stavros Hadjimiltiades; Vlassios Ninios; Nikolaos Mezilis; Barry J Maron; Ioannis H Styliadis
Journal:  Hellenic J Cardiol       Date:  2014 Mar-Apr

Review 2.  Hypertrophic Cardiomyopathy: Clinical Update.

Authors:  Jeffrey B Geske; Steve R Ommen; Bernard J Gersh
Journal:  JACC Heart Fail       Date:  2018-04-11       Impact factor: 12.035

Review 3.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

4.  Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy.

Authors:  Alberto Foà; Valentina Agostini; Claudio Rapezzi; Iacopo Olivotto; Barbara Corti; Luciano Potena; Elena Biagini; Sofia Martin Suarez; Matteo Rotellini; Franco Cecchi; Pierluigi Stefano; Raffaele Coppini; Cecilia Ferrantini; Maria L Bacchi Reggiani; Ornella Leone
Journal:  Int J Cardiol       Date:  2019-03-28       Impact factor: 4.164

5.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

Review 6.  The pathology of hypertrophic cardiomyopathy.

Authors:  S E Hughes
Journal:  Histopathology       Date:  2004-05       Impact factor: 5.087

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

8.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

9.  Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts.

Authors:  Giuseppe Galati; Ornella Leone; Ferdinando Pasquale; Iacopo Olivotto; Elena Biagini; Francesco Grigioni; Emanuele Pilato; Massimiliano Lorenzini; Barbara Corti; Alberto Foà; Valentina Agostini; Franco Cecchi; Claudio Rapezzi
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

Review 10.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.